Literature DB >> 16126451

The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!

Jodi M Thomson1, Robert A Bonomo.   

Abstract

Beta-lactam antibiotics are the cornerstone of our antibiotic armamentarium. By inhibiting bacterial cell wall synthesis, they are highly effective against Gram-positive and Gram-negative bacteria. Unfortunately, bacteria have evolved sophisticated resistance mechanisms to combat the lethal effects of beta-lactam antibiotics. Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae are all able to evade killing by penicillins, cephalosporins and carbapenems. This multi-drug resistant phenotype that challenges health care workers worldwide is caused by an array of resistance determinants. These include altered expression of outer membrane proteins and efflux pumps, along with an increasing arsenal of beta-lactamases. Future strategies in beta-lactam design must take into account the complex nature of resistance in Gram-negative pathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126451     DOI: 10.1016/j.mib.2005.08.014

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  55 in total

Review 1.  ISCR elements: novel gene-capturing systems of the 21st century?

Authors:  Mark A Toleman; Peter M Bennett; Timothy R Walsh
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

Review 2.  Molecular mechanisms of host-pathogen interactions and their potential for the discovery of new drug targets.

Authors:  Volker Briken
Journal:  Curr Drug Targets       Date:  2008-02       Impact factor: 3.465

Review 3.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Computational redesign of the SHV-1 beta-lactamase/beta-lactamase inhibitor protein interface.

Authors:  Kimberly A Reynolds; Melinda S Hanes; Jodi M Thomson; Andrew J Antczak; James M Berger; Robert A Bonomo; Jack F Kirsch; Tracy M Handel
Journal:  J Mol Biol       Date:  2008-05-29       Impact factor: 5.469

5.  Detection of VIM- and IMP-type Metallo-Beta-Lactamase Genes in Acinetobacter baumannii Isolates from Patients in Two Hospitals in Tehran.

Authors:  Saba Davoodi; Mohammad Ali Boroumand; Saeed Sepehriseresht; Leila Pourgholi
Journal:  Iran J Biotechnol       Date:  2015-03       Impact factor: 1.671

6.  Characterization and purification of a bacteriocin from Lactobacillus paracasei subsp. paracasei BMK2005, an intestinal isolate active against multidrug-resistant pathogens.

Authors:  Kamel Bendjeddou; Michel Fons; Pierre Strocker; Djamila Sadoun
Journal:  World J Microbiol Biotechnol       Date:  2011-12-03       Impact factor: 3.312

7.  Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant Acinetobacter baumannii at a Tertiary Care Hospital from South India.

Authors:  Dheepa Muthusamy; S Sudhishnaa; Appalaraju Boppe
Journal:  J Clin Diagn Res       Date:  2016-09-01

8.  Antibiotic-resistant soil bacteria in transgenic plant fields.

Authors:  Sandrine Demanèche; Hervé Sanguin; John Poté; Elisabeth Navarro; Dominique Bernillon; Patrick Mavingui; Walter Wildi; Timothy M Vogel; Pascal Simonet
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

9.  Evolution of broad spectrum β-lactam resistance in an engineered metallo-β-lactamase.

Authors:  Song Sun; Wei Zhang; Bengt Mannervik; Dan I Andersson
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

10.  In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors:  Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal:  J Antimicrob Chemother       Date:  2009-06-02       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.